1naresh

Array
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

)
1nareshArray
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

)

Table 1: Baseline patient characteristics
Placebo (N = 208)^* IV tPA (N = 172)^* IV-IA tPA (N = 80)^† P
Median (iqr)
Baseline 
    Age 66 (58–72) 69 (59–74) 65 (54.5–75) .229
    Gender (% female) 44 42 50 .513
    bNIHSS 17 (13–22) 17 (14–21) 18 (14–21) .857
    Glucose (mM) 7.0 (6.0–8.75) 6.9 (5.8–9.5) 6.2 (5.6–7.3) .0098
    bASPECTS 8 (6–10) 8 (6–10) 7 (4–9) .0003
    bASPECTS > 7 (%) 62.5 57.0 37.5 .001
    Onset-to-treat time (min) 108.5 (89–150) 90 (88–149) 140 (110–158) <.001
Outcomes 
    Death (%) 24 20 16 .361
    mRS 0–1 (%) 18 33 30 .002
    mRS 0–2 (%) 28 40 43 .016
    NIHSS 0–1 (%) 15 25 28 .013
    sICH (%) 0.96 5.2 6.3 .014
Note:—tPA indicates tissue plasminogen activator; iqr, interquartile range; bNIHSS, baseline National Institutes of Health Stroke score; ASPECTS, Alberta Stroke Program Early CT score; bASPECTS, baseline ASPECT score; mRS, modified Rankin Scale; sICH, symptomatic intracerebral hemorrhage.
* From a subset of the NINDS tPA Stroke Study.
† From the IMS-1 Trial.